{"id":"NCT00597584","sponsor":"Affymax","briefTitle":"Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis","officialTitle":"AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-07","completion":"2010-01","firstPosted":"2008-01-18","resultsPosted":"2012-07-30","lastUpdate":"2013-03-08"},"enrollment":823,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Renal Failure","Chronic Kidney Disease","Anemia"],"interventions":[{"type":"DRUG","name":"peginesatide","otherNames":["Omontys","Hematide","AF37702 Injection"]},{"type":"DRUG","name":"Epoetin alfa or Epoetin beta","otherNames":["Epogen","Neorecormon"]}],"arms":[{"label":"Peginesatide","type":"EXPERIMENTAL"},{"label":"Epoetin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the safety and efficacy of peginesatide in the maintenance treatment of anemia in participants on dialysis.","primaryOutcome":{"measure":"Mean Change in Hemoglobin Between Baseline and the Evaluation Period","timeFrame":"Baseline to Weeks 29-36","effectByArm":[{"arm":"Peginesatide","deltaMin":11.2,"sd":0.553},{"arm":"Epoetin","deltaMin":11.21,"sd":0.546}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":84,"countries":["United States","Bulgaria","France","Germany","Italy","Poland","Romania","Spain","United Kingdom"]},"refs":{"pmids":["23343061","23343062"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":268,"n":542},"commonTop":["Muscle spasms","Nausea","Dyspnoea","Diarrhoea","Headache"]}}